Introduction
Prostate cancer is the most frequently diagnosed cancer in American men . Androgen plays an important role in the development and growth of prostate carcinoma (Kokontis and Liao, 1999) . Androgen ablation is an eective treatment for advanced prostate cancer. Unfortunately, after a period of remission, a relapse occurs due to the acquisition of androgen-independent tumor growth. A better understanding of the regulation of androgen signaling in human prostate cancer cells will enhance our ability to design a rational therapeutic strategy for prostate cancer treatment.
The androgen receptor (AR) is a member of the nuclear receptor (NR) superfamily (Bentel and Tilley, 1996) . NRs have conserved domain structures (Freedman, 1999) . At the N-terminus is the ligandindependent transcriptional activation domain (AF-1). The central domain contains two zinc ®nger structures that are involved in DNA binding (DBD). The C-terminal region is the ligand binding domain (LBD) . In addition, an essential ligand-dependent transactivation domain (AF-2) is localized in the Cterminus of the LBD. The binding of androgen to AR triggers the contact of AR to its speci®c androgen response elements (AREs) in the promoters of androgen-responsive genes and the interactions of AR with other transcription cofactors. These interactions allow the activation or repression of genes that regulate development, dierentiation and maintenance of male reproductive functions (Trapman and Cleutjens, 1997) .
The activity of NR is regulated by transcriptional coactivators and corepressors (Freedman, 1999; Horwitz et al., 1996; Torchia et al., 1998) . These coregulator complexes modulate NR-mediated gene activation by interaction with general transcription factors or by remodeling chromatin. Many coregulators of AR have been described, most of them are suggested to function as coactivators of AR (a detailed description of these factors can be found at http:// www.mcgill.ca/androgendb/). Many nuclear coactivators contain one or multiple copies of the a-helical LXXLL signature motif (where L is Leucine and X is any amino acid residue). Biochemical studies have demonstrated that the LXXLL signature motif mediates ligand-dependent coactivator-NR interactions or coactivator ± coactivator interactions (Heery et al., 1997; Torchia et al., 1997) .
In studies aimed at the understanding of STAT (Signal Transducer and Activator of Transcription) signaling (Darnell, 1997) , our laboratory has uncovered a novel protein family termed PIAS (Protein Inhibitor of Activated STAT), of which four members have been identi®ed ± PIAS1, PIAS3, PIASx (consisting of two splicing variants: PIASxa and PIASxb), and PIASy (Shuai, 1999; 2000) . PIAS1 and PIAS3 interact with Stat1 and Stat3, respectively. PIAS can block the DNA binding activity of STAT and can inhibit STAT-mediated gene activation (Chung et al., 1997; Liu et al., 1998) .
Recently, two independent yeast two-hybrid screens using the DNA binding domain of AR as the bait have identi®ed ARIP3 (Androgen Receptor Interacting Protein 3), a rat homologue of human PIASxa, as well as PIAS1 as AR-interacting proteins (Moilanen et al., 1999; Tan et al., 2000) . Subsequent studies suggest that ARIP3/PIASxa and PIAS1 can function as coactivators of AR. We have carried out a systematic analysis on the roles of various PIAS members of AR signaling in prostate cancer cells. We found that PIAS1, PIAS3 and PIASy are expressed in human prostate. PIASy, unlike other PIAS proteins, is a potent inhibitor of AR-mediated gene activation in prostate cancer cells. PIASy interacts with AR but does not aect the DNA binding activity of AR. Mutational analysis identi®ed an essential function of an LXXLL signature motif at the N-terminus of PIASy for the transrepression activity of PIASy. Our results suggest that PIASy is a transcriptional corepressor of AR. Thus, androgen signaling can be positively or negatively regulated by PIAS proteins in prostate cancer cells.
Results

PIAS1, PIAS3 and PIASy are expressed in human prostate
To study the role of PIAS proteins in prostate cancer, we ®rst performed Northern blot analysis to determine which PIAS family members are expressed in human prostate. It has been shown previously that PIAS3 is ubiquitously expressed in a variety of human tissues including prostate (Chung et al., 1997) . A human tissue blot was probed for the expression of PIAS1, PIASx and PIASy. Two messages with the sizes of 2.3 and 3.5 kb, probably resulting from dierent RNA processing, were detected in various human tissues including prostate when the blot was probed with PIASy cDNA (Figure 1a) . Similarly, two major forms of PIAS1 messages with the sizes of 2.6 and 7.4 kb were present in prostate and other tissues (Figure 1b) . However, PIASxa is mainly expressed in human testis ( Figure  1c) , consistent with the result obtained when ARIP3, a rat homologue of PIASxa, was used as the probe (Moilanen et al., 1999) (expression of PIASxa was detectable in other tissues when the blot was overexposed (data not shown)). A similar expression pattern of PIASxb was also detected (data not shown). We conclude that PIAS1, PIAS3, and PIASy are expressed in human prostate tissue.
We next wanted to con®rm that PIAS proteins are indeed expressed in prostate epithelial cells. LNCaP human prostate cancer cells were subjected to biochemical fractionation, and expression of PIASy, PIAS3, and PIAS1 was examined by Western blotting using speci®c anti-PIAS antibodies (Chung et al., 1997; Liu et al., 1998 Liu et al., , 2001 ). PIASy, PIAS1 and PIAS3 can be detected in the nuclear fractions ( Figure 1d ). The nuclear locatization of PIAS1 is consistent with the pattern seen in the germinal epithelium of human testis by immunohistochemistry using the same PIAS1 antibody (Tan et al., 2000) .
Distinct effects of PIAS proteins on AR-mediated gene activation in prostate cancer cells
We examined the eects of PIAS1, PIAS3 and PIASy proteins on AR-mediated gene activation in the LNCaP cell line. LNCaP cells express a mutated AR but androgen response appears to be normal in these cells (McDonald et al., 2000) . Expression vectors encoding Flag-tagged PIAS1, PIAS3 or PIASy were cotransfected together with a wild-type AR expression vector and a luciferase reporter (PSA-E4 Luc) with the androgen-responsive promoter of PSA (Prostate Speci®c Antigen) ( Figure 2 ). Transfected cells were untreated or treated with R1881 (methyltrienolone, a synthetic androgen). We found that in the absence of PIAS proteins, R1881 induced a 10 ± 15-fold activation of the PSA reporter. In the presence of an increasing amount of PIAS1, the R1881-induced luciferase activity was dramatically enhanced, up to 70-fold when 2 mg of PIAS1 was employed (Figure 2a ). PIAS3 showed similar eects as PIAS1 (Figure 2b ). Most interestingly, unlike other PIAS proteins, PIASy caused a dose-dependent inhibition of R1881-induced luciferase activity. In fact, when 1 mg of PIASy was used, the AR-mediated gene activation was completely inhibited (Figure 2c ). PIAS proteins did not show signi®cant eects on the basal level of reporter transcription in the absence of R1881 treatment (data not shown). These results suggest that PIASy, in contrast to other PIAS proteins, is a potent inhibitor of AR signaling. Thus, dierent members of the PIAS family have distinct eects on AR-mediated gene activation in prostate cancer cells.
Competitive effects of PIASy and PIAS1 on AR-mediated gene activation
To test the hypothesis that PIASy and other PIAS proteins can in¯uence androgen response in a competitive fashion, LNCaP cells were transiently tranfected with the PSA luciferase reporter together with AR, PIAS1, and PIASy. The dramatic activation of AR-mediated transcription in the presence of PIAS1 was abolished in the presence of PIASy ( Figure  3 ). These results imply that the relative expression level of PIASy and other PIAS proteins in prostate cancer cells can in¯uence the overall androgen response.
The NH2-terminal portion of PIASy interacts with the DBD domain of AR It has been previously shown that ARIP3/PIASxa and PIAS1 can interact with the DBD of AR (Moilanen et al., 1999; Tan et al., 2000) . We next tested if PIASy can also interact with the DBD of AR by in vitro binding assays. Glutathione-S-transferase (GST) or GST fused to AR-DBD (GST-AR-DBD) proteins were bound to glutathione-agarose beads and mixed with 35 S-labeled PIASy.
35
S-labeled luciferase protein was used as a control. A speci®c interaction between AR-DBD and PIASy was observed (Figure 4a ). When a portion of PIASy containing the NH2-terminal 406 amino acid residues (PIASy-N) was tested, the ARPIASy interaction remained intact (Figure 4a ). Similar amounts of GST and GST-AR-DBD were present on beads (Figure 4b) . Thus, the NH2-terminal region of PIASy can directly interact with the DBD domain of AR.
PIASy does not influence AR DNA bindings PIAS1 and PIAS3 can block the DNA binding activity of STATs in vitro (Chung et al., 1997; Liu et al., 1998) . We wished to determine if PIASy aects the DNA binding activity of AR by electrophoretic mobility shift analysis (EMSA). An anity puri®ed His-tagged DNA binding domain of AR (His-DBD) was incubated with 32 P-labeled ARE oligonucleotide in the presence or absence of GST or GST-PIASy fusion proteins. The DNA binding ability of AR was not aected by either GST or GST-PIASy at various concentrations used (Figure 5a ). The lack of a PIASy-AR-DBD supershift band was probably due to the instability of such a complex under the conditions used in these assays. The His-tagged AR-DBD showed no binding to a mutant ARE oligonucleotide, con®rming the binding speci®city of His-tagged AR-DBD (Figure 5b) . We conclude that PIASy does not aect the DNA binding activity of AR.
The PIASy LXXLL motif is required for repression A putative a-helical LXXLL signature motif is present at the NH2-terminal of PIASy (Figure 6a ). The LXXLL motif has been shown to mediate NRcoactivator or coactivator ± coactivator interactions. We next tested if the PIASy LXXLL motif is involved in PIASy-AR interaction by in vitro GST pull-down analysis. A mutant PIASy (PIASy-AA) with mutations in the LXXLL motif (LXXLL to LXXAA) was generated. Both 35 S-labeled wild-type PIASy and mutant PIASy-AA proteins bound to GST-AR-DBD but not GST beads ( Figure 6b , the upper panel). Similar amounts of GST and GST-AR-DBD were present in each sample ( Figure 6b , the lower panel). Thus, the LXXLL signature motif is not involved in PIASy-AR interaction.
To test if the LXXLL motif is required for the transrepression activity of PIASy, LNCaP cells were transiently transfected with the PSA luciferase reporter together with wild-type PIASy or PIASy-AA mutant. While wild-type PIASy eectively inhibited the R1881-induced luciferase activity, the PIASy-AA mutant protein completely lost its ability to inhibit ARmediated gene activation (Figure 7a ). To further con®rm these results, similar luciferase assays were performed in 293T cells which are known to allow for ecient transfection. Again, wild-type PIASy, but not PIASy-AA mutant, was able to inhibit the R1881-induced luciferase activity in a dose dependent manner (Figure 7b, upper panel) . Interestingly, PIASy-AA mutant protein enhanced the reporter activity when expressed at higher levels. This dominant negative eect of PIASy-AA, which is able to interact with AR but lacks the transrepression activity, may result from the competition of PIASy-AA with the endogenous PIASy for binding to AR. Protein blot analysis indicated that wild-type PIASy and mutant PIASy-AA were expressed at comparable levels ( Figure 7b,  lower panel) . These results demonstrate that the LXXLL motif of PIASy, although not required for PIASy-AR interaction, is essential for PIASy to repress AR-mediated gene activation.
Discussion
To understand the role of PIAS proteins in androgen signaling in prostate cancer cells, we systematically examined and compared the eects of PIAS1, PIAS3 and PIASy, which are expressed in human prostate, on the transcriptional activity of AR in prostate cancer cells. Our studies revealed two signi®cant ®ndings: (1) PIAS proteins display distinct eects on AR-mediated gene activation in prostate cancer cells. PIAS1 and PIAS3 enhance while PIASy represses the transcriptional activity of AR. These results support a hypothesis that the relative level of PIAS expression in prostate cancer cells may contribute partly to the overall androgen response; (2) PIASy acts as a transcriptional corepressor of AR. The N-terminal LXXLL signature motif of PIASy is essential for the transrepression activity of PIASy.
To the best of our knowledge, PIAS represents the ®rst known example of a family of related proteins that can both positively and negatively regulate ARmediated transcriptional activity. PIAS proteins contain several conserved domains, including a zinc binding motif and an acidic region. In addition, all Figure 2 Eects of PIAS proteins on AR-mediated gene activation in a human prostate carcinoma cell line. LNCaP cells were transiently transfected with empty expression plasmid, exogenous wild-type human AR expression plasmid, and increasing doses (0.1, 1.0 and 2.0 mg) of PIAS expression plasmids as indicated. PSA-E4 Luc and pRL-TK were included as reporter and control vectors, respectively. Cells were grown in phenol redfree RPMI with charcoal-stripped fetal bovine serum and harvested 24 h after stimulation. Fold induction was calculated from paired samples grown in the presence or absence of 10 nM R1881. Total DNA content was kept constant in all wells. Results are displayed as the average of at least three independent experiments+s.e. Figure 3 Competitive eects of PIASy and PIAS1 on ARmediated gene activation. LNCaP cells were transiently transfected with 1 mg PIAS1 and PIASy expression vectors as indicated. Exogenous hAR was expressed in all wells. PSA-E4 Luc reporter and pRL-TK control plasmids were included as in Figure 2 Oncogene PIAS proteins and androgen-mediated gene-activation M Gross et al PIAS proteins, except PIASy, contain a serine/ threonine region at the COOH terminus (Shuai, 2000) . The domain(s) responsible for the observed distinct eects of PIAS proteins on AR signaling is not known. Future studies on the molecular basis of the PIAS speci®city on androgen signaling should enhance our understanding of the regulation of androgenmediated gene activation in prostate cancer cells.
Several lines of evidence presented in this report suggest that PIASy may function as a transcriptional corepressor of AR. First, PIASy directly interacts with the DBD domain of AR. Second, PIASy represses the transcriptional activity of AR without aecting the GST pull-down experiments were performed as described in Figure 4 except that the LXXLL-AA mutant PIASy was also included in the assays as indicated DNA binding activity of AR. Third, an NH2-terminal LXXLL signature motif is required for the transrepression activity of PIASy, but is not involved in PIASy-AR interaction. The LXXLL signature motif was originally identi®ed in several NR coactivators (Heery et al., 1997; Torchia et al., 1997) . The LXXLL motif can mediate NR-coactivator or coactivator ± coactivator interactions (Darimont et al., 1998; Glass and Rosenfeld, 2000; McInerney et al., 1998; Rachez et al., 1999) . Recently, highly related sequences are also found to be present in NR corepressor (Hu and Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999) . It is possible that the LXXLL motif of PIASy is involved in interacting with other corepressors which are required for PIASy to repress transcription. Consistent with this hypothesis, the PIASy-AA mutant displays a dominant negative eect on AR-mediated gene activation (Figure 7) . Further studies are required to understand the exact role of this LXXLL motif in PIASy-mediated repression on AR.
PIAS proteins are known to be negative regulators of STATs. The discovery of the involvement of PIAS in AR signaling suggests that PIAS proteins may have a broad role in transcriptional regulation. In STAT signaling, PIAS1 and PIAS3 can inhibit the DNA binding activity of Stat1 and Stat3, respectively. In this paper, we showed that PIASy can inhibit AR-mediated gene activation without blocking the DNA binding activity of AR, suggesting PIASy is a corepressor of AR. Consistently, our most recent studies indicate that PIASy can also function as a corepressor of Stat1 (Liu et al., 2001) . Thus, PIAS proteins can modulate transcription through distinct mechanisms.
PIAS proteins interact with STATs only in cells stimulated with cytokines (Chung et al., 1997; Liu et al., 1998 Liu et al., , 2001 ). The cytokine-dependent PIAS ± STAT interaction is due to the ability of PIAS to interact with the dimeric form, but not the monomeric form of STAT . Whether the PIAS ± AR interaction in prostate cancer cells requires androgen stimulation is not known. However, at least in yeast cells, the PIAS1 ± AR interaction is dependent on ligand stimulation (Tan et al., 2000) . The association of PIAS with a transcription factor only upon ligand stimulation can allow the eective participation of PIAS in transcriptional regulation in response to a variety of cellular signals.
Materials and methods
Cells
293T and LNCaP cells were maintained in DMEM and phenol red-free RPMI media, respectively. All media contained 10% fetal bovine serum (Life Technologies, Inc.), 100 u/ml penicillin and 100 mg/ml streptomycin.
Immunoblotting
Rabbit polyclonal antibodies were raised against the carboxyterminal regions of PIAS1, PIAS3, and PIASy as previously described (Chung et al., 1997; Liu et al., 2001; Tan et al., 2000) . LNCaP cells were separated by biochemical fractionation into cytoplasmic and nuclear extracts as described (Shuai et al., 1992) . Extracts were standardized for protein concentration, resolved on a 7.5% polyacrylamide-sodium dodecyl sulfate gel (SDS ± PAGE), and analysed by standard immunoblotting procedures.
Plasmids FLAG-PIASy was constructed by subcloning the full-length human PIASy cDNA into the BglII ± SalI sites of pCMV-FLAG vector. FLAG-PIASy-AA was produced by PCRbased site-directed mutagenesis using primers to produce L23 to A and L24 to A missense mutations and subcloned into pCMV-FLAG. GST-PIASy, GST-PIASy-N (1 ± 406), and GST-PIASy AA were produced by subcloning PIASy and PIASy AA cDNAs into pGEX4T-1 (Amersham Pharmacia Biotech, Inc., Piscataway, NJ, USA). The coding regions of all vectors were con®rmed by sequencing. PSA-E4 Luc containing a 496-kp region from the PSA enhancer upstream of the adenovirus E4 core promoter and luciferase gene and pET11dHis6ARDBD which codes for a His-tagged protein encompassing AR amino acids 544 ± 634 have been previously reported (Huang et al., 1999) . The plasmid, pGST-AR-DBD, which codes for glutathione-S-transferase fused to AR residues 544 ± 634 has also been previously described (Tan et al., 2000) .
Transfections and reporter assays
293T were transfected via the calcium phosphate method (Liu et al., 1998) . Brie¯y, cells were plated at 5610 5 cells per well into a 6-well plate and transfected with 1 ± 3 mg total DNA. Empty vector DNA was included to equalize amount of total DNA transfected in each experiment. After transfection, cells were grown in appropriate media supplemented with 10% charcoal-dextran stripped fetal bovine serum (Omega Scienti®c). Cells were stimulated with methyltrienolone (R1881; Dupon-NEN) for 18 ± 24 h before harvest. A b-galactosidase reporter vector was included in each well to adjust for transfection eciency. LNCaP cells were transfected with TFX-50 (Promega Corp., Madison, WI, USA) as previously described (Abreu-Martin et al., 1999) . The Renilla luciferase reporter vector, pRL-TK, was included in all wells to control for transfection eciency. Fire¯y and Renilla luciferase activities were measured (Promega Corp). A portion of each lysate was analysed on a 7.5% SDS ± PAGE gel followed by immunoblotting using the M2-FLAG monoclonal antibody (Sigma).
Electrophoretic mobility shift assay (EMSA)
EMSA analysis was performed as described (Khan et al., 1993) . Brie¯y, anity puri®ed AR-DBD produced in Escherichia coli (Huang et al., 1999) was incubated with or without GST-fusion protein for 5 min at room temperature in gel shift buer. Approximately, 40 fmol oligonucleotide probe containing a consensus AR DNA binding site or mutant AR DNA binding site (Huang et al., 1999) was added and incubated for an additional 20 min at room temperature. The complexes were resolved on a 4.5% non-denaturing polyacrylamide gel. Gels were dried and analysed by phosphoimaging (Molecular Dynamics, Inc.).
GST pull-down assays
The E. coli strain BL21 (DE3) was transformed with pGEX4T-1 (Clontech) or pGST-AR-DBD. Overnight cultures were diluted into 0.5 liters of LB medium and grown to OD 600 of 0.8 ± 1.0. Cultures were induced with 1 mM isopropyl-l-thio-b-D-galactopyranoside at 378C for 2 h and GST or GST-AR-DBD puri®ed with glutathione-agarose as previously described (Chung et al., 1997) . PIASy and PIASy-AA coding regions were cloned into pcDNA3.1 (Invitrogen, Inc.) and 35 S-labeled protein synthesized using TNT Quick Coupled Transcriptional/Translation kit (Promega Corp.).
Equal amounts of agarose-immobilized GST or GST-AR-DBD were incubated with 20 mcl of protein mixture in PBS (pH 7.5) containing 1 mg/ml BSA, 0.02% NP-40, 1 mg/ml aprotonin, 1 mg/ml leupeptin, 1 mM DTT and 1 mM PMSF essentially as previously described (Tan et al., 2000) . Beads were thoroughly washed and bound proteins were removed and analysed on a 10% SDS ± PAGE gel which was dried and developed by¯uorography. An aliquot of bound material was analysed by Coomassie staining of a 15% SDS ± PAGE gel to con®rm equal protein loading.
